IMDX – insight molecular diagnostics inc. (US:NASDAQ)

News

Oncocyte (NASDAQ:IMDX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Oncocyte (NASDAQ:IMDX) is now covered by analysts at Weiss Ratings. They set a "sell (d-)" rating on the stock.
Oncocyte (NASDAQ:IMDX) was upgraded by analysts at Wall Street Zen t
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating [Seeking Alpha]
This Biotech Stock Is Up 158% in a Year. What's Driving It Higher? [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com